Positron emission computed tomography/single photon emission computed tomography in Parkinson disease.
10.1097/CM9.0000000000000836
- Author:
Nian-Ting YAO
1
;
Qian ZHENG
2
;
Zi-Qian XU
2
;
Jian-Hong YIN
2
;
Lin-Guang LU
1
;
Qi ZUO
1
;
Su YANG
1
;
Chun-Lin ZHANG
3
;
Ling JIAO
2
Author Information
1. Guizhou Medical University, Guiyang, Guizhou 550004, China.
2. Department of Neurology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China.
3. Department of Biology, Guizhou Medical University, Guiyang, Guizhou 550004, China.
- Publication Type:Journal Article
- From:
Chinese Medical Journal
2020;133(12):1448-1455
- CountryChina
- Language:English
-
Abstract:
Parkinson disease (PD) is the second-most common neurodegenerative disorder. Its main pathological mechanism is the selective degeneration and deletion of dopaminergic neurons in the dense part of the substantia nigra and the damage of dopaminergic neurons caused by the abnormal deposition of a Lewy body, leading to a decreased dopamine level. Positron emission computed tomography (PET)/single photon emission computed tomography (SPECT) is a molecular imaging technology that can directly or indirectly reflect changes in molecular levels by using a specific tracer. With the research and development on the tracers of related enzymes for labeling dopamine transporter and dopamine receptor and for being involved in dopamine formation, this imaging technology has been applied to all aspects of PD research. It not only contributes to clinical work but also provides an important theoretical basis for exploring the pathological mechanism of PD at a molecular level. Therefore, this review discusses the application value of PET/SPECT in PD in terms of early diagnosis, disease severity evaluation, clinical manifestations, differential diagnosis, and pathological mechanism.
